Alaunos Therapeutics terminated its license agreement with Precigen to develop T-cell receptors for cancer treatment, citing strategic priorities and the upcoming expiration of a patent in 2026, while also exploring various strategic alternatives and progressing its obesity drug program with plans for testing in 2024 and 2025.